Correlation between sKL and Nrf2 plasma levels and calcium oxalate urolithiasis.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 20 03 2023
accepted: 23 04 2023
medline: 28 6 2023
pubmed: 18 5 2023
entrez: 17 5 2023
Statut: ppublish

Résumé

To investigate the relationship between plasma levels of sKL and Nrf2 and calcium oxalate calculi. The clinical data of 135 patients with calcium oxalate calculi treated in the Department of Urology of the second affiliated Hospital of Xinjiang Medical University from February 2019 to December 2022, and 125 healthy persons who underwent physical examination in the same period were collected and divided into healthy group and stone group. The levels of sKL and Nrf2 were measured by ELISA. Correlation test was used to analyze the risk factors of calcium oxalate stones, logistic regression analysis was used to analyze the risk factors of calcium oxalate stones, and ROC curve was used to evaluate the sensitivity and specificity of sKL and Nrf2 in predicting urinary calculi. Compared with the healthy group, the plasma sKL level in the stone group decreased (111.53 ± 27.89 vs 130.68 ± 32.51), while the plasma Nrf2 level increased (300.74 ± 114.31 vs 246.74 ± 108.22). There was no significant difference in the distribution of age and sex between the healthy group and the stone group, but there were significant differences in plasma levels of WBC, NEUT, CRP, BUN, BUA, SCr, BMI, and eating habits. The results of correlation test showed that the level of plasma Nrf2 was positively correlated with SCr (r = 0.181, P < 0.05) and NEUT (r = 0.144 P < 0.05). Plasma sKL was not significantly correlated with Nrf2 (r = 0.047, P > 0.05), WBC (r = 0.108, P > 0.05), CRP (r = - 0.022, P > 0.05), BUN (r = - 0.115, P > 0.05), BUA (r = - 0.139, P > 0.05), SCr (r = 0.049, P > 0.05), and NEUT (r = 0.027, P > 0.05). Plasma Nrf2 was not significantly correlated with WBC (r = 0.097, P > 0.05), CRP (r = 0.045, P > 0.05), BUN (r = 0.122, P > 0.05), and BUA (r = 0.122, P > 0.05); (r = 0.078, P > 0.05) had no significant correlation. Logistic regression showed that elevated plasma sKL (OR 0.978, 95% CI 0.969 ~ 0.988, P < 0.05) was a protective factor for the occurrence of calcium oxalate stones, BMI (OR 1.122, 95% CI 1.045 ~ 1.206, P < 0.05), dietary habit score (OR 1.571, 95% CI 1.221 ~ 2.020, P < 0.05), and WBC (OR 1.551, 95% CI 1.423 ~ 1.424, P < 0.05). Increased NEUT (OR 1.539, 95% CI 1.391 ~ 1.395, P < 0.05) and CRP (OR 1.118, 95% CI: 1.066 ~ 1.098, P < 0.05) are risk factors for the occurrence of calcium oxalate stones. Plasma sKL level decreased and Nrf2 level increased in patients with calcium oxalate calculi. Plasma sKL may play an antioxidant role in the pathogenesis of calcium oxalate stones through Nrf2 antioxidant pathway.

Identifiants

pubmed: 37198517
doi: 10.1007/s11255-023-03615-z
pii: 10.1007/s11255-023-03615-z
doi:

Substances chimiques

Calcium Oxalate 2612HC57YE
Antioxidants 0
Calcium SY7Q814VUP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1671-1676

Subventions

Organisme : Natural Science Foundation of Xinjiang
ID : 81760128

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature B.V.

Références

Liu Y, Chen Y, Liao B et al (2018) Epidemiology of urolithiasis in Asia[J]. Asian J Urol 5(4):205–214
doi: 10.1016/j.ajur.2018.08.007 pubmed: 30364478 pmcid: 6197415
Maihemuti M, Du heng, Tuerhong D, et al (2017) Effect of Klotho protein on renal oxidative stress in rats with calcium oxalate nephrolithiasis. Chinese J Urol. 38(12):941–945
Makoto K-O (2019) The Klotho proteins in health and disease. J Nat Rev Nephrol. 15:27–44
doi: 10.1038/s41581-018-0078-3
Jian X, Joonho Y, Sung-Wan An et al (2015) Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 26:1150–1160
doi: 10.1681/ASN.2014040325
Navarro-González Juan F, Dolores S-N, Javier D-C et al (2018) Effects of Pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease. J Diabetes Care 41:1817–1820
doi: 10.2337/dc18-0078
Sivandzade F, Prasad S, Bhalerao A et al (2019) NRF2 and NF-қB interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches[J]. Redox Biol 21:101059
doi: 10.1016/j.redox.2018.11.017 pubmed: 30576920
Meng X, Feng Y, Ying Le et al (2021) Klotho protects against diabetic kidney disease via AMPK- and ERK-mediated autophagy. Acta Diabetol. https://doi.org/10.1007/s00592-021-01736-4
doi: 10.1007/s00592-021-01736-4 pubmed: 33768379
Bishop K, Momah T, Ricks J (2020) Nephrolithiasis[J]. Prim Care 47(4):661–671
doi: 10.1016/j.pop.2020.08.005 pubmed: 33121635
Wagner CA (2021) Etiopathogenic factors of urolithiasis. Factores etiopatogénicos de la urolitiasis. Arch Esp Urol 74(1):16–23
pubmed: 33459618
Gao X, Sun Z, Ma G et al (2021) Reduced plasma levels of α-klotho and their correlation with klotho polymorphisms in elderly patients with major depressive disorders. Front Psychiatry. 12:682691
doi: 10.3389/fpsyt.2021.682691 pubmed: 34721095 pmcid: 8548667
He Q, Babcook MA, Shukla S et al (2016) Obesity-initiated metabolic syndrome promotes urinary voiding dysfunction in a mouse model. Prostate 76(11):964–976
doi: 10.1002/pros.23185 pubmed: 27040645 pmcid: 4946024
Drew DA, Katz R, Kritchevsky S et al (2017) Association between Soluble Klotho and change in kidney function: the health aging and body composition study. J Am Soc of Nephrol. https://doi.org/10.1681/ASN.2016080828
doi: 10.1681/ASN.2016080828
Ahmatjan B, Ruotian L, Rahman A et al (2023) Klotho inhibits the formation of calcium oxalate stones by regulating the Keap1-Nrf2-ARE signaling pathway. Int Urol Nephrol 55(2):263–276
doi: 10.1007/s11255-022-03398-9 pubmed: 36336747
Chen WY (2020) Soluble Alpha-Klotho alleviates cardiac fibrosis without altering cardiomyocytes renewal. Int J Mol Sci 21(6):2186
doi: 10.3390/ijms21062186 pubmed: 32235720 pmcid: 7139467
Maltese G, Psefteli PM, Rizzo B et al (2017) The anti-ageing hormone klotho induces Nrf2-mediated antioxidant defences in human aortic smooth muscle cells. J Cell Mole Med. https://doi.org/10.1111/jcmm.12996
doi: 10.1111/jcmm.12996
Wei C, Bin, et al (2018) Klotho protein inhibits H2O2-induced oxidative injury in endothelial Cells via regulation of PI3K/Akt/Nrf2/HO-1 Pathways. Can J Physiol Pharmacol. https://doi.org/10.1139/cjpp-2018-0277
doi: 10.1139/cjpp-2018-0277 pubmed: 28910549
Lindberg K, Amin R, Moe OW et al (2014) The kidney is the principal organ mediating klotho effects. J Am Soc Nephrol 25(10):2169–2175
doi: 10.1681/ASN.2013111209 pubmed: 24854271 pmcid: 4178446
Wolf M, An SW, Nie M et al (2014) Klotho Up-regulates Renal Calcium Channel Transient Receptor Potential Vanilloid 5 (TRPV5) by Intra- and Extracellular N-glycosylation-dependent Mechanisms. J Biol Chem. https://doi.org/10.1074/jbc.M114.616649
doi: 10.1074/jbc.M114.616649 pubmed: 25378396 pmcid: 4276853

Auteurs

Baihetiyaer Aihemaitijiang (B)

Urology Department, Second Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.

Liu Ruotian (L)

Department of Urology, The Second People's Hospital of Henan Province, Zhengzhou, 450000, Henan Province, China.

Yang Qi (Y)

Department of Surgery, Neijiang Traditional Chinese Medicine Hospital, Neijiang, 641099, Sichuan, China.

Mulati Mahemuti (M)

Urology Department, Second Affiliated Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China. 969279694@qq.com.
Department of Urology, The Second People's Hospital of Henan Province, Zhengzhou, 450000, Henan Province, China. 969279694@qq.com.
Department of Surgery, Neijiang Traditional Chinese Medicine Hospital, Neijiang, 641099, Sichuan, China. 969279694@qq.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH